Comparison of the adherence of the oral pharmacokinetically enhanced formulation of amoxicillin/clavulanic acid 2,000/125 mg twice daily with that of the standard formulation of amoxicillin/clavulanic acid 500/125 mg thrice daily C. Llor, N. Sierra, S. Hernández, C. Bayona, A. Moragas, M. Miravitlles (Tarragona, Valls, Barcelona, Spain)
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Session: Drug delivery and pharmacokinetics II Session type: Thematic Poster Session Number: 4551
Disease area: Respiratory infectionsRating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Llor, N. Sierra, S. Hernández, C. Bayona, A. Moragas, M. Miravitlles (Tarragona, Valls, Barcelona, Spain). Comparison of the adherence of the oral pharmacokinetically enhanced formulation of amoxicillin/clavulanic acid 2,000/125 mg twice daily with that of the standard formulation of amoxicillin/clavulanic acid 500/125 mg thrice daily. Eur Respir J 2010; 36: Suppl. 54, 4551
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Efficacy and safety of oral pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg twice daily versus oral amoxicillin/clavulanate 1000/125 mg three times daily for the treatment of bacterial community-acquired pneumonia (CAP) Source: Eur Respir J 2001; 18: Suppl. 33, 137s Year: 2001
Comparative trial of cefuroxime 250 mg with probenecid 250 mg with cefuroxime 500 mg in lower respiratory tract infection Source: Eur Respir J 2001; 18: Suppl. 33, 137s Year: 2001
3-day azithromycin (AZM) 500 mg qd versus 10-day clarithromycin (CLA) 500 mg bid for acute exacerbation of chronic bronchitis (AECB) in adults Source: Eur Respir J 2002; 20: Suppl. 38, 545s Year: 2002
The effect of esomeprazole 40mg once or twice daily on asthma outcome Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009
Salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than fluticasone propionate 100 μg bid plus montelukast 10 mg once daily in reducing exacerbations Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001
No differences in early or late community-acquired pneumonia outcomes in patients treated with IV ceftriaxone plus oral clarithromycin extended-release tablets versus IV levofloxacin plus oral placebo Source: Eur Respir J 2003; 22: Suppl. 45, 335s Year: 2003
The salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than oral montelukast 10 mg od as a first line therapy in mild and moderate asthmatics Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001
Ciclesonide once daily (80 mg/d, 160 mg/d) versus fluticasone propionate twice daily (250 mg/d) in the treatment of patients with persistent asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010
Comparison of tobramycin 80 mg (IV-Preparation) and 300 mg solution for inhalation in cystic fibrosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005
Erdosteine 600mg, but not placebo and NAC 1200mg, restores airway response to inhaled salbutamol 200mcg in COPD Source: Annual Congress 2007 - Mechanisms and new treatments of COPD Year: 2007
Comparable efficacy of ciclesonide 160 μg once daily and budesonide 200 μg twice daily in patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005
Efficacy of the novel very long-acting β2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006
Once daily ciclesonide (80 µg or 320 µg) is equally effective as budesonide 200 µg given twice daily: a 12-week study in asthma patients Source: Eur Respir J 2003; 22: Suppl. 45, 410s Year: 2003
A comparison of once daily (evening) versus twice daily budesonide therapy from a new multi-dose dry powder inhaler versus twice daily therapy from a conventional dry powder inhaler in children Source: Eur Respir J 2001; 18: Suppl. 33, 121s Year: 2001
Effect of codeine (30mg) with paracetamol (650mg) on post bronchoscopy coughing –an open labeled placebo control trial Source: International Congress 2019 – Interventional pulmonology: diagnostic techniques and obstructive airway disease Year: 2019
Urinary cortisol levels following 400 mcg budesonide twice daily from a novel multi-dose dry powder inhaler compared to a conventional dry powder inhaler in children Source: Eur Respir J 2001; 18: Suppl. 33, 289s Year: 2001
Ciclesonide 160 μg once daily compared with fluticasone propionate 250 μg twice daily in maintenance therapy of patients with stable asthma Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Pharmacokinetics of consecutive oral moxifloxacin 400 mg/day in patients with respiratory tract infection Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010
Research on in vitro release kinetics of isoniazid (IZN) and omeprazole from oral tablets Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Inhaled budesonide 800 μg once daily versus 400 μg twice daily in patients with mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 97s Year: 2001